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Abstract: The segmentation of the in vitro fertilization (IVF) cycle, consisting of the freezing of
all embryos and the postponement of embryo transfer (ET), has become popular in recent years,
with the main purpose of preventing ovarian hyperstimulation syndrome (OHSS) in patients with
high response to controlled ovarian stimulation (COS). Indeed cycle segmentation (CS), especially
when coupled to a GnRH-agonist trigger, was shown to reduce the incidence of OHSS in high-risk
patients. However, CS increases the economic costs and the work amount for IVF laboratories. An
alternative strategy is to perform a fresh ET in association with intensive luteal phase pharmacological
support, able to overcome the negative effects of the GnRH-agonist trigger on the luteal phase and on
endometrial receptivity. In order to compare these two strategies, we performed a retrospective, real-
life cohort study including 240 non-polycystic ovarian syndrome (PCO) women with expected high
responsiveness to COS (AMH >2.5 ng/mL), who received either fresh ET plus 100 IU daily human
chorionic gonadotropin (hCG) as luteal support (FRESH group, n = 133), or cycle segmentation
with freezing of all embryos and postponed ET (CS group, n = 107). The primary outcomes were:
implantation rate (IR), live birth rate (LBR) after the first ET, and incidence of OHSS. Overall,
significantly higher IR and LBR were observed in the CS group than in the FRESH group (42.9%
vs. 27.8%, p < 0.05 and 32.7% vs. 19.5%, p < 0.05, respectively); the superiority of CS strategy was
particularly evident when 16–19 oocytes were retrieved (LBR 42.2% vs. 9.5%, p = 0.01). Mild OHSS
appeared with the same incidence in the two groups, whereas moderate and severe OHSS forms
were observed only in the FRESH group (1.5% and 0.8%, respectively). In conclusion, in non-PCO
women, high responders submitted to COS with the GnRH-antagonist protocol and GnRH-agonist
trigger, CS strategy was associated with higher IR and LBR than the strategy including fresh ET
followed by luteal phase support with a low daily hCG dose. CS appears to be advisable, especially
when >15 oocytes are retrieved.
Keywords: luteal phase support; corpus luteum function; GnRH agonist trigger; hCG; GnRH
antagonist protocol; IVF; ovarian hyperstimulation syndrome
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1. Introduction
In reproductive physiology, the luteinizing hormone (LH) is mandatory for maintain-
ing corpus luteum function and promotes the secretion of progesterone and growth factors
involved in embryo implantation and placentation [1,2].
In in vitro fertilization (IVF), suppression of hypothalamic activity by GnRH analogs/
antagonists is required during controlled ovarian stimulation (COS) of multiple follicles
in order to avoid a premature LH surge. Final oocyte maturation is commonly triggered
by administering exogenous human chorionic gonadotropin (hCG). Indeed, due to its
strong biological activity and its relatively long half-life [3], hCG is able to sustain the
multiple corpora lutea throughout the luteal phase. Nevertheless, in order to compensate
for the supra-physiological pre-ovulatory levels of estradiol, observed during COS [4,5],
the addition of progesterone is needed for optimal endometrial receptivity and to avoid
early pregnancy loss [6,7].
In women who have a large ovarian reserve (defined as “high responders”), the
administration of exogenous hCG in the presence of supraphysiological estradiol levels is
associated with an increased risk of ovarian hyperstimulation syndrome (OHSS) [8], partly
caused by the stimulating effects of hCG on ovarian production of vasoactive factors [9,10].
The risk of OHSS may be minimized using “short protocols” with GnRH antagonists
to accomplish COS, and triggering ovulation with a bolus of GnRH-agonist instead of
hCG [11–13]. With a GnRH-agonist trigger, a physiological peak of LH is responsible
for final oocyte maturation. Whereas the number of retrieved mature oocytes is usually
comparable after either a GnRH-agonist or hCG trigger [11], the rapid drop of endogenous
LH concentration observed after a GnRH-agonist trigger negatively affects corpus luteum
function, in turn worsening endometrial receptivity [14]. Indeed, luteal phase deficiency
after GnRH-agonist trigger administration is extremely frequent, resulting in lower im-
plantation and clinical pregnancy rates [15], even when progesterone supplementation
is used.
In order to solve this problem, freezing of all embryos and delaying embryo transfer
to the following ovarian cycle has been proposed. This strategy is defined as cycle segmen-
tation (CS) or “freeze-all” strategy. With CS, the risk of OHSS is strongly reduced, whereas
IVF efficacy is maintained [16]. However, such an approach increases both the economic
costs and the amount of work for the IVF unit. Furthermore, some patients consider the
delay of embryo transfer (ET) negatively, and their anxiety level increases, enhancing the
risk of drop-out.
As alternatives to CS, some forms of intensive pharmacological supplementation of
the luteal phase after the GnRH-agonist trigger have been suggested. Among others, the
addition of estradiol to progesterone at high doses [17,18], or the administration of 1500
IU hCG the day of oocyte pick up (OPU) [14,19]. Promising results have been obtained
with the daily administration of a very low (100 IU) dose of hCG in the luteal phase, which
was proposed in a small series of patients who underwent GnRH-agonist trigger and fresh
ET [20].
The aim of the present study was to compare the outcome of this approach, that
is, fresh ET followed by a very low daily dose of hCG, with CS, applied to a group of
non-PCO patients treated with a GnRH-analogue trigger, who were expected to be high
responders on the basis of their ovarian reserve markers. The primary end-points were
the implantation rate (IR), the live birth rate (LBR), and the ovarian hyperstimulation
syndrome (OHSS) incidence.
2. Results
The baseline clinical characteristics of the women included in the study are shown in
Table 1. Table 2 shows the outcome of IVF in the two study groups.
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Table 1. Clinical baseline characteristics of the patients receiving fresh embryo transfer (ET) plus
human chorionic gonadotropin (hCG) luteal supplementation (FRESH group) vs. those undergoing
cycle segmentation with freezing of all embryos and delayed ET (CS group). Data are expressed as
mean ± standard deviation.
Clinical Baseline Characteristics FRESH(n = 133)
CS
(n = 107) p-Value
Age (years) 34.7 ± 4.1 34.8 ± 4.1 0.80
BMI (kg/cm2) 22.6 ± 3.7 22.8 ± 4.6 0.79
Basal AMH (ng/mL) 5.3 ± 2.9 7.4 ± 5.6 <0.01
Basal (day 3) FSH (UI/L) 6.4 ± 1.4 6.4 ± 1.7 0.91
Basal (day 3) LH (UI/L) 6.6 ± 3.1 7.3 ± 3.5 0.14
Antral follicle count (AFC) 19.9 ± 6.8 26.9 ± 10.1 <0.01
LH: luteinizing hormone.
Table 2. In vitro fertilization (IVF) outcomes of patients receiving fresh ET plus hCG luteal supple-
mentation (FRESH group) vs. those undergoing cycle segmentation with freezing of all embryos
and delayed ET (CS group). Data are expressed as mean ± standard deviation and median (IQR),
if appropriate, for quantitative variables and percentages for qualitative variables. * Endometrial
thickness in the FRESH group was measured during oocyte pick up (OPU), whereas in the CS group,
it was measured the day after LH urinary peak during the spontaneous cycle in which ET with
thawed embryo was performed. ** In both groups, only the first ET was considered. OHSS: ovarian
hyperstimulation syndrome.
IVF Cycle Outcomes FRESH(n = 133)
CS
(n = 107) p-Value













































Implantation rate (%) ** 27.8 42.9 <0.05
Clinical pregnancy rate/first ET% ** 26.3 40.2 <0.05
Live birth rate/first ET% ** 19.5 32.7 <0.05
Mild OHSS% 12 12.1 0.98
Moderate OHSS% 1.5 0 -
Severe OHSS% 0.8 0 -
Women in the CS group had higher ovarian reserve markers (AMH and AFC): al-
though the mean and total dose of exogenous FSH was comparable in the two groups,
they finally got a higher number of retrieved oocytes and blastocysts (Table 2). However,
the mean embryo score was comparable in the two groups. The higher responsiveness to
COS in the CS group did not influence the calculation of the implantation rate (IR), clinical
pregnancy rate (CPR), or the live birth rate (LBR), as it was performed taking into account
only the first ET, and did not cumulatively consider all ETs. As per the protocol, all viable
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and transferable blastocysts in the CS group were vitrified, but those after the first ET were
not considered to calculate the outcomes.
Overall, we observed significantly higher IR, CPR and LBR after the first ET in the CS
group than in the FRESH group (IR = 42.9% vs. 27.8%, p < 0.05; CPR = 40.2% vs. 26.3%,
p < 0.05; LBR = 32.7% vs. 19.5%, p < 0.05, respectively).
Due to the significant association between the number of retrieved oocytes and the
study groups (p < 0.01), patients were then stratified according to the number of retrieved
oocytes (Table 3; A = 8–11 oocytes, B = 12–15 oocytes, C = 16–19 oocytes) to compare the
FRESH and CS groups in three subsets of patients with almost no significant differences
in the baseline characteristics and with comparable responsiveness to COS. Even after
normalizing for the response to COS, which virtually abolished all effects due to different
ovarian reserve markers in the two “naïve” groups, we observed that the CS strategy led to
higher, although not statistically significant, percentage of positive hCG test and LBR, and
that its superiority was particularly remarkable when >15 oocytes were retrieved (Table 3).
These results were confirmed after fitting logistic regression models in the three subgroups
of women, where LBR was the dependent variable, and the study group (CS vs. FRESH),
AMH and estradiol levels were the independent variables: after adjusting for AMH and
estradiol levels, the CS group showed a higher probability of LBR in all subgroups, with
the association being nearly significant (OR 4.43, CI95% 0.84; 23.2, p = 0.07, data not shown)
among women with >15 retrieved oocytes.
Table 3. Clinical baseline characteristics and IVF outcome of the patients receiving fresh ET plus
hCG luteal supplementation (FRESH group) vs. those undergoing cycle segmentation with freezing
of all embryos and delayed ET (CS group). Women were stratified according to the number of
retrieved oocytes in order to normalize for the ovarian response to COS: A = 8–11 retrieved oocytes;
B = 12–15 retrieved oocytes; C = 16–19 retrieved oocytes. Data are expressed as mean ± standard
deviation or median (IQR), as appropriate, if not otherwise stated. ** In both groups, only the first ET
was considered.
A (8–11 Retrieved Oocytes) FRESH(n = 52)
CS
(n = 30) p-Value
Age (years) 34.8 ± 4.3 34.9 ± 4.2 0.94
BMI (kg/cm2) 23.1 ± 3.4 23.6 ± 6.2 0.63
Basal AMH (ng/mL) 4.15 (2.8–6) 5.2 (3.3–6.5) 0.13
Estradiol at ovulation trigger
(pg/mL) 2070 (1529–2920.5) 2485.5 (1746–4268) 0.06
Positive hCG test % (n) 25 (13) 30 (9) 0.62
Live birth rate/first ET% (n) ** 21.2 (11) 23.3 (7) 1.00
B (12–15 Retrieved Oocytes) FRESH(n = 60)
CS
(n = 32)
Age (years) 34.7 ± 4.1 34.4 ± 3.7 0.73
BMI (kg/cm2) 22.1 ± 3.3 22.5 ± 3.4 0.63
Basal AMH (ng/mL) 5.45 (3.4–6.3) 6.3 (3.8–8.7) 0.07
Estradiol at ovulation trigger
(pg/mL) 2284.5 (1609.5–3090) 3254.5 (2342–4311) <0.01
Positive hCG test % (n) 31.7 (19) 40.6 (13) 0.49
Live birth rate/first ET % (n) ** 21.7 (13) 28.1 (9) 0.61
C (16–19 Retrieved Oocytes) Fresh(n = 21)
CS
(n = 45)
Age (years) 34.3 ± 3.8 35.1 ± 4.3 0.48
BMI (kg/cm2) 22.8 ± 5.5 22.4 ± 4.1 0.76
Basal AMH (ng/mL) 5.7 (4.3–6.5) 6.9 (4.4–9.8) 0.07
Estradiol at ovulation trigger
(pg/mL) 1918 (1583–3024) 3345 (2445–4363) <0.01
Positive hCG test % (n) 33.3 (7) 51.1 (23) 0.19
Live birth rate/first ET% (n) ** 9.5 (2) 42.2 (19) 0.01
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A total number of 29 events of mild OHSS were observed, with no significant difference
between the two groups (12% vs. 12.1%). Moderate and severe OHSS were observed with
two and one cases in the FRESH group, respectively (1.5% and 0.8%, respectively, Table 3),
whereas no cases were reported in the CS group (Table 2).
3. Discussion
In recent years, the freezing of all available embryos followed by thaw ET in one of the
subsequent spontaneous cycles, namely known as “cycle segmentation”, has become quite
popular. The main reason for this is the efficacy in preventing OHSS in high-risk patients,
among which are both women with PCO ovaries and those with very marked responsive-
ness to COS, the so-called “high responders” [21–25]. These patients are usually submitted
to a COS protocol, including the use of low-dose gonadotropins plus a GnRH-antagonist
to prevent premature LH peak. The trigger of final follicular maturation is obtained using
a single bolus of GnRH-agonist, which stimulates the release of an endogenous LH peak.
In comparison with the classical hCG trigger, the GnRH-agonist-stimulated LH peak
remarkably lowers the risk of inducing OHSS, but it is shorter and biologically weaker,
resulting in insufficient support for the corpus luteum during the luteal phase [26]. This
does not represent an issue when all embryos are vitrified and ET is postponed to one of
the following cycles.
Besides the documented efficacy in preventing OHSS, CS may offer further advan-
tages, such as a more favorable pattern of endometrial gene expression and increased
receptivity [26], both linked to the absence of detrimental endometrial effects caused by
excessive E2 levels and/or premature P elevation [27]. Indeed, COS has been associated
with altered angiogenesis, impaired placentation [28–30], and higher instability of the
reproductive tract microbiota [31], all factors able to reduce the likelihood of blastocyst
implantation. As a matter of fact, in specific subgroups of patients, CS have been reported
to be associated with higher implantation rates [21,32] and better perinatal and obstet-
ric outcomes [33,34] than the conventional fresh ET strategy. It is debated whether the
application of CS might be extended even to cases not necessarily at risk of OHSS.
However, the weak points of CS mean it is not always convenient; it is undoubtedly
more time-consuming and economically expensive for the IVF laboratory, and it may even
represent an additional emotional burden for the patients, who may live with increasing
anxiety the delay of their ET.
For these reasons, even in patients at risk of OHSS, alternative strategies allowing fresh
ET after the use of GnRH-analogue trigger have been conceived [6]. In fact, there is evidence
that even very low levels of hCG might adequately support the luteal phase in GnRH-
agonist triggered cycles, even without the addition of exogenous progesterone [20,35].
Over the last few years, the strategy of performing fresh ET and supplement the luteal
phase with very low doses of hCG has been used in our IVF unit, as an alternative to
traditional CS, in the case of non-PCO patients with ovarian reserve markers and a wide
ovarian reserve (AMH > 2.5 ng/mL, AFC > 15), who were expected to deliver a high
response to COS without the very high OHSS risk typical of patients with PCOS. When
these patients obtained less than 20 oocytes at OPU, and the ultrasound (US) endometrial
appearance at OPU was satisfactory (thickness > 7 mm and type 1 echogenicity), a fresh
ET was scheduled, and the luteal phase was supplemented using 100 IU/d s.c. hCG. In
contrast, when >19 oocytes were retrieved and/or the endometrium appeared thinner
than 7 mm, or with type 2 or 3 US appearance, all blastocysts were vitrified, and ET was
postponed in a subsequent, natural cycle with suitable endometrial characteristics.
The main finding of the present retrospective investigation is that the CS strategy
allowed the obtaining of higher IR, CPR, and LBR, considering only the first ET than the
strategy including fresh ET and hCG supplementation. This suggests that a very low
daily dose of hCG, although overall safe with respect to the risk of OHSS, is probably
inadequate to compensate for the negative effect of the trigger GnRH-agonist bolus on the
luteal function.
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Indeed, women in the CS group had significantly higher AMH and AFC and, as
expected, a better ovarian responsiveness to COS, more oocytes retrieved, and more
available blastocysts. It is well known that there is a strong relationship between the
number of oocytes and the LBR in a fresh IVF cycle, with optimal outcomes with between
15–20 eggs [36]. However, even normalizing for ovarian responsiveness through stratifica-
tion in three subgroups of patients with a comparable number of retrieved oocytes and
similar basal “a priori” characteristics, the analyses showed a better performance of the CS
strategy, especially evident among patients retrieving >15 oocytes.
Notably, in the FRESH group, the LBR/ET was lower in the subgroup with 16–19
retrieved oocytes than in the two subgroups with fewer oocytes (p < 0.01), suggesting that
when peak estradiol levels are higher, the inadequacy of hCG supplementation in restoring
endometrial receptivity is probably more marked [37].
Conversely, the LBR/ET in the CS group showed an opposite trend, steadily increasing
with the number of retrieved oocytes, an observation that confirms the association between
ovarian responsiveness and the likelihood of getting a live birth [36].
As for safety issues, the strategy of performing a fresh ET with very low dose hCG
supplementation was associated with an overall rate of OHSS (2.2% moderate plus severe
OHSS rate), which compares favorably with the incidence of 3–6% commonly reported
overall for IVF cycles [38]. However, it is questionable whether this rate of OHSS could
still be acceptable, as the elimination of OHSS represents one of the main current goals of
IVF treatments.
4. Materials and Methods
The study was designed as a retrospective, real-life cohort study and was performed
at the IVF Unit of Sant’Anna University Hospital after obtaining the approval of the
Institutional Review Board, in accordance with the Helsinki Committee requirements
(n. 0040486, 23/04/2020).
Among 2312 women undergoing IVF in the years 2016–2019, 434 were classified as
expected high responders, according to their ovarian reserve markers (AMH > 2.5 ng/mL
and antral follicle count (AFC) > 15). Of those women, 298 had regular menstrual cycles,
no signs of hyperandrogenism, and no PCO appearance of the ovaries at transvaginal US;
they were included in the study as non-PCO expected high responders.
The remaining 136 women had polycystic ovary syndrome (PCO) according to ESHRE
guidelines [39] and were excluded from the study. PCO patients, in fact, are known to
represent a specific population that is at very high risk of developing severe OHSS, and
according to our protocols, CS is mandatory.
Other 58 women with multifollicular non-PCO ovaries were excluded from the study
after OPU because >19 oocytes were retrieved, and, again, our protocols forced us to
perform CS due to the well-known, direct relationship between the number of retrieved
oocytes and the risk of severe OHSS.
Therefore, finally, we compared 133 non-PCO high responders receiving fresh ET plus
luteal phase hCG supplementation (FRESH group) vs. 107 comparable patients receiving
cycle segmentation (CS group).
COS, OPU, and IVF or ICSI were performed as described in Appendix A. Both groups
received a single subcutaneous injection of 0.2 mg Triptorelin Acetate (Decapetyl, Ferring,
Germany) as an ovulation trigger. Embryos were assessed morphologically on day 2
using the 1–10 point scale score by Holte et al. [40], and then again on day 5 according
to The Istanbul Consensus Workshop [41]. Embryos that progressed to the expanded
blastocyst stage on day 5 (score 3) showed compacted inner cell mass (score 1), and
cohesive trophoectoderm (score 1 or 2) were selected for the first transfer in both groups.
The ET was performed as previously described [42].
The decision on whether patients would receive fresh ET or CS was taken during OPU
and was based on the endometrial US appearance; when the endometrial thickness was
<7 mm and/or its appearance was not trilinear (so it was type 2 or 3), CS was performed. In
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contrast, when the endometrial thickness was ≥7 mm, with a trilinear (type 1) appearance,
fresh ET was chosen.
In the FRESH group, women received a single blastocyst fresh ET on day 5. Starting
the day after OPU, 100 IU/day of hCG (Gonasi HP, Ibsa, Lugano, Switzerland) were
administered subcutaneously for 14 days.
In the CS group, a standard vitrification protocol was used to freeze all blastocysts. ET
was performed in one of the following menstrual cycles, monitoring spontaneous ovulation
by urinary LH-detection kit (Clearblue® Ovulation Test, Swiss Precision Diagnostics,
Switzerland). ET with one thawed blastocyst was performed only whether endometrial
thickness reached at least 7 mm, with an endometrial US type 1 appearance the day after
urinary LH peak. The luteal phase was supplemented with 180 mg/day intra-vaginal
natural progesterone (Crinone 8, Merck, Germany), starting 48 h after the LH peak and
continuing for 14 days.
In case of a positive pregnancy test, transvaginal ultrasound (TV-US) examination was
scheduled two weeks later.
The implantation rate (IR) was calculated, taking into account also the biochemical
pregnancies. The clinical pregnancy rate (CPR) was calculated considering only pregnancies
that were confirmed at TV-US (presence of a gestational sac) two weeks after the positive
pregnancy test. Live birth rate (LBR) was calculated with live birth defined as a live-born
infant after >24 weeks of gestation.
The number of retrieved oocytes is a well-known factor affecting the LBR [36]; to
minimize the impact of this variable, a sub-analysis was performed, in which FRESH and
CS groups were compared after stratification for the number of retrieved oocytes into three
subgroups (8–11, 12–15, or 16–19).
Safety was evaluated considering the incidence of OHSS, whose severity was assessed
as previously described [43]. Statistical comparison between the two study groups was
performed using the GraphPad Prism V7 software package and Stata16; the Student’s t-test
or the non-parametric Wilcoxon rank-sum test were used, as appropriate, for continuous
variables (shown as mean ± SD and/or median and interquartile range (IQR)), whereas
the Chi squared or Fisher’s tests were used for categorical variables (shown as percentages
and absolute frequencies). Multivariable analysis models were then used to investigate the
independent effects of the study group (CS vs. FRESH) on LBR in the three subgroups of
women, stratified according to the number of retrieved oocytes. Logistic regression models
were fit using LBR as dependent variable and study group, with AMH and estradiol levels
as independent variables. All statistical tests were two-sided, and a p-value of 0.05 was
considered the significance threshold.
5. Conclusions
In conclusion, to the best of our knowledge, this is the largest study comparing IVF
outcomes in non-PCO high responders submitted to COS with GnRH-antagonist protocol,
GnRH-agonist trigger, and either CS or fresh ET with hCG luteal phase support.
With the limitation of its retrospective nature, the present study shows that the strategy
of CS is associated with higher IR, CPR, and LBR than the alternative strategy, including
fresh ET plus repeated very low daily dose of hCG.
If confirmed using a larger sample size and in a randomized controlled trial, the
present findings would help to orient clinical decisions, with the final aim of improving
IVF outcomes.
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Appendix A
All the enrolled non-PCO expected high responders underwent COS with the GnRH-
antagonist regimen, using recombinant FSH (Gonal F, Merck, Darmstadt, Germany or
Puregon, MSD, Readington, NJ, USA). The FSH starting dose ranged from 100 to 150 IU
according to age and BMI and was then adjusted from stimulation day 5–7 according to the
ovarian response at the first checkpoint, during which transvaginal US (TV-US) and serum
estradiol (E2) measurement were performed. From stimulation day 5, a daily injection
(0.25 mg/d s.c) of GnRH-antagonist (Cetrorelix Merck, Darmstadt, Germany or Orgalutran,
MSD, Readington, NJ, USA) was added. Follicular growth was monitored by TV-US and
serum E2 every 2–3 days, and when at least two follicles reached 18 mm mean diameter,
with appropriate E2 circulating levels, ovulation was triggered by a single subcutaneous
injection of 0.2 mg Triptorelin Acetate (Decapetyl, Ferring, Saint-Prex, Switzerland). Ovu-
lation trigger was performed in the same way in the FRESH and CS groups. OPU was
performed approximately 36 h after Triptorelin Acetate injection by US-guided aspiration
under local anesthesia (paracervical block). Follicular fluid was immediately observed
under a stereomicroscope; cumulus-oocyte complexes (COCs) were washed in buffered
medium (Flushing medium, Cook Ltd., Limerick, Ireland), and oocytes were inseminated
within 4 h from OPU using either conventional IVF or ICSI, according to the quality of the
semen sample. Normal fertilization was confirmed when the presence of two pronuclei
(2PN) and the extrusion of the second polar body were observed 16–18 h after oocyte
insemination. Zygotes were placed in 4-well dishes (Thermo Ficher Scientific, Waltham,
MA, USA) and cultured in pre-equilibrated cleavage medium (Cook Ltd., Limerick, Ireland)
overlain with mineral oil (Culture Oil, Cook Ltd., Limerick, Ireland).
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